Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease.
JACC Case Rep
; 4(20): 1327-1330, 2022 Oct 19.
Article
en En
| MEDLINE
| ID: mdl-36299643
ABSTRACT
Compound heterozygous familial hypercholesterolemia patients are phenotypically similar to homozygous familial hypercholesterolemia patients, present with significant elevations of low-density lipoprotein cholesterol, and are at risk of cardiovascular disease. Although new treatment options are emerging, the stepwise approach to the use of different therapies has not been well described. (Level of Difficulty Intermediate.).
ACLY, adenosine triphosphate-citrate lyase; ANGPTL3, angiopoietin-like protein 3 inhibitor; ASCVD, atherosclerotic cardiovascular disease; FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; LDL-R, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9; atherosclerosis; dyslipidemias; hypercholesterolemia; lipid metabolism disorders
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
JACC Case Rep
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos